by EmpathiCSubstanceS | Aug 17, 2022 | Psilocybin Magic Mushroom
The present pilot study demonstrated that up to 2 mg of psilocybin delivered as a slow intravenous injection produces short-lived but typical drug effects that are psychologically and physiologically well tolerated. With appropriate care, this study supports the...
by EmpathiCSubstanceS | Aug 17, 2022 | Psychedelic Research
Participants’ responses to psilocybin were qualitatively similar to those described in other populations. Abstinence did not increase significantly in the first 4 weeks of treatment (when participants had not yet received psilocybin), but increased significantly...
by EmpathiCSubstanceS | Aug 17, 2022 | Psilocybin Magic Mushroom, Psychedelic Research
Robust activations to the memories were seen in limbic and striatal regions in the early phase and the medial prefrontal cortex in the late phase in both conditions (P<0.001, whole brain cluster correction), but there were additional visual and other sensory...
by EmpathiCSubstanceS | Aug 12, 2022 | Bipolar Disorder, Chronic Pain, Kambo, LSD, MDMA Sassafras Molly, Microdosing, NN-Dimethyltryptamine, OCD, Psilocybin Magic Mushroom, Psychedelic Medicine
COULD AN OVERACTIVE IMMUNE SYSTEM make you depressed? In the late 1990s, psychiatrist Andrew Miller and his colleagues began to notice that patients with cancer, cardiovascular disease, obesity and Crohn’s disease—all conditions that cause higher than normal levels of...
by EmpathiCSubstanceS | Aug 11, 2022 | Psychedelic Research
After two blinded experimental sessions, the active group had significantly greater reductions in CAPS-IV total scores from baseline than the control group [MMRM estimated mean difference (SE) between groups − 22.0 (5.17), P < 0.001]. The between-group Cohen’s d...
